Evaxion Biotech gains as cancer therapy gets FDA's fast track tag

Evaxion A/S

19/01/2023 15:20

** Evaxion Biotech's shares  EVAX.O  rise 11.25% to $1.78
    ** Drug developer says the U.S. Food and Drug Administration
(FDA) has granted fast track designation to co's personalized
cancer therapy, EVX-01, in combination with Merck & Co Inc's 
 MRK.N  cancer drug, Keytruda  urn:newsml:reuters.com:*:nGNXc37p8M
    ** Fast track designation is granted by the FDA to
facilitate development and expedite the review of therapies with
potential to treat a serious condition where there is an unmet
medical need
    ** EVAX fell ~60% last year
 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))